A Phase IV open, randomized, controlled study to evaluate the safety and immunogenicity of a pediatric presentation (0.25 ml) of the virosomal hepatitis A virus (HAV) vaccine HAVpur in healthy young children aged between, and including, 18 months to 47 months, using a 0/6 month immunization schedule.

Trial Profile

A Phase IV open, randomized, controlled study to evaluate the safety and immunogenicity of a pediatric presentation (0.25 ml) of the virosomal hepatitis A virus (HAV) vaccine HAVpur in healthy young children aged between, and including, 18 months to 47 months, using a 0/6 month immunization schedule.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Hepatitis A vaccine inactivated (Primary)
  • Indications Hepatitis A
  • Focus Pharmacodynamics
  • Sponsors Crucell
  • Most Recent Events

    • 30 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top